Strategic divestitures Recent asset divestiture to DKSH Management and rights transfer for Meliane across 30 markets indicate Bayer's ongoing portfolio optimization. Sales opportunities may exist in contract manufacturing, distribution partnerships, or co-branded support services to ensure seamless market coverage for remaining products.

Digital capabilities Launch of digital pest monitoring tool MagicTrap 2 and utilization of tech stack like SAP and Blazor suggest Bayer is investing in digital solutions and data-driven operations. There is potential to offer onboarding, integration, or analytics platforms that enhance their digital health and farm solutions, as well as security and compliance services.

Innovation focus Active development of durable cancer treatment regimens and award-winning manufacturing facilities signal a robust R&D and manufacturing strategy. Opportunities exist to provide clinical trial support, regulatory affairs services, precision manufacturing, or high-throughput analytics and process optimization solutions.

Global footprint Bayer operates across multiple regions with a sizable, albeit smaller, revenue base in the provided data. There is potential to expand into or optimize regional supply chain partnerships, translational marketing, and region-specific regulatory consulting to support market entry or expansion for Bayer Consumer Care products.

Operational optimization Significant headcount reductions noted in 2024–2026 imply ongoing efficiency drives. This creates potential opportunities for services around workforce analytics, change management, outsourced operations, and IT-enabled process improvements to maintain productivity during restructuring.